NX-06

NX-06 is a preclinical peptide drug candidate developed by Beijing Neoletix Biological Technology for the treatment of thrombosis. It is a product of the company's proprietary NanoT (Nano-Targeting) platform, which specializes in creating chemically synthesized peptides that mimic the high specificity and affinity of single-domain antibodies (nanobodies). While the NanoT platform is primarily marketed for its ability to modulate the tumor microenvironment (TME) in oncology, NX-06 represents an application of this targeting technology to vascular disorders. The specific molecular target and the precise mechanism by which this TME-focused platform exerts an antithrombotic effect have not been publicly disclosed.